coronavirusassoci
diseas
first
identifi
china
pandem
caus
batderiv
betacoronaviru
name
share
homolog
sar
merscov
respons
past
outbreak
china
middl
east
spread
china
first
infect
describ
decemb
respons
respiratori
symptom
lead
acut
respiratori
distress
syndrom
cytokin
storm
shown
patient
develop
fatal
complic
observ
past
coronaviru
infect
manag
includ
ventilatori
support
broadspectrum
antivir
drug
empir
util
target
therapi
vaccin
develop
base
upon
limit
knowledg
pathogenesi
potenti
role
antirheumat
drug
may
hypothes
act
direct
antivir
target
host
immun
respons
antimalari
drug
commonli
use
rheumatolog
may
alter
lysosom
proteas
mediat
viral
entri
cell
demonstr
efficaci
improv
infect
may
interfer
cytokin
storm
sever
case
use
tocilizumab
shown
good
outcom
small
cohort
baricitinib
antivir
antiinflammatori
properti
checkpoint
inhibitor
could
role
treatment
rheumat
diseas
patient
take
immunosuppress
drug
recommend
maintain
chronic
therapi
prevent
infect
avoid
social
contact
paus
immunosuppress
case
infect
nation
intern
registri
creat
collect
data
rheumat
patient
coronaviru
emerg
past
month
clinic
syndrom
caus
novel
betacoronaviru
name
sever
acut
respiratori
syndrom
sar
first
report
late
decemb
wuhan
china
diseas
offici
name
world
health
organ
februari
follow
outbreak
acut
respiratori
ill
hubei
provinc
sinc
earliest
report
infect
spread
mani
countri
worldwid
signific
rate
infect
itali
current
account
infect
case
associ
fatal
declar
pandem
march
pandem
import
implic
patient
rheumat
diseas
particularli
undergo
varieti
immunosuppress
therapi
seem
obviou
immunosuppress
therapi
increas
risk
sever
diseas
infect
mani
patient
tendenc
stop
immunosuppress
treatment
especi
highli
impact
area
italian
lombardi
region
howev
import
note
mani
commonli
use
immunosuppress
drug
jak
kinas
inhibitor
tocilizumab
propos
andor
use
treatment
select
patient
develop
frequent
fatal
clinic
sequala
known
cytokin
releas
syndrom
cr
also
refer
cytokin
storm
follow
infect
data
http
receiv
march
accept
march
chang
rapidli
diseas
trajectori
hypothes
issu
whether
continu
treat
rheumat
diseas
patient
need
address
field
rheumatolog
medic
subspecialti
sinc
agent
may
benefici
specif
phase
complic
diseas
posit
singl
strand
nucleotid
rna
viru
includ
open
read
frame
encod
protein
belong
coronavirida
famili
phylogenet
data
consist
presenc
bat
reservoir
subsequ
spill
human
popul
sequenc
data
show
share
high
degre
sequenc
homolog
betacoronaviru
isol
bat
term
suggest
chines
chrysanthemum
bat
like
origin
nonetheless
unknown
anim
sold
seafood
market
wuhan
hypothes
act
intermedi
host
first
case
common
contact
market
bat
present
bat
hibern
decemb
addit
share
gene
homolog
sar
coronaviru
sarscov
respons
outbreak
middl
east
respiratori
syndrom
mer
cov
respons
infect
saudi
arabia
respect
virus
intermedi
host
includ
civet
camel
respect
human
serv
termin
host
persontoperson
transmiss
alreadi
establish
infect
reason
mediat
respiratori
droplet
current
data
also
suggest
elderli
patient
compromis
immun
system
significantli
higher
risk
higher
mortal
infect
suspect
patient
develop
fever
cough
myalgia
fatigu
bilater
interstiti
pneumonia
diagnos
patient
earliest
seri
ground
glass
opac
patchi
infiltr
chest
visual
computer
tomographi
around
case
rapidli
worsen
respiratori
failur
acut
respiratori
distress
syndrom
ard
requir
admiss
intens
care
unit
icu
mortal
rate
approxim
highest
older
age
patient
particularli
chronic
diseas
current
hospit
icu
current
specif
drug
andor
vaccin
infect
prompt
use
sever
broadspectrum
antivir
molecul
addit
anim
model
studi
diseas
test
potenti
vaccin
present
miss
antirheumat
drug
possibl
therapi
antimalari
baricitinib
drug
usual
use
rheumatolog
field
target
host
immun
respons
seem
potenti
interfer
infect
potenti
benefit
studi
patient
fig
pathogenesi
remain
unclear
model
assay
reveal
high
degre
homolog
receptor
bind
domain
sarscov
coronavirus
express
surfac
glycoprotein
term
spike
bind
host
receptor
viral
entri
identifi
angiotensinconvert
enzym
receptor
express
matur
lung
epitheli
cell
enterocyt
kidney
proxim
tubular
cell
endotheli
cell
receptor
bind
lysosom
proteas
cleav
spike
protein
releas
signal
peptid
facilit
viral
entri
cell
mechan
may
target
interrupt
therapi
chloroquin
antimalari
drug
preliminari
data
demonstr
may
clinic
benefit
manag
infect
patient
determin
improv
imag
shorten
diseas
cours
note
hydroxychloroquin
share
mechan
action
chloroquin
better
safeti
profil
frequent
use
particularli
connect
tissu
diseas
potent
antivir
effect
chloroquin
vitro
result
physiologicallybas
pharmacokinet
model
load
dose
mg
oral
follow
mg
daili
four
day
reach
three
time
potenc
chloroquin
therefor
promis
drug
prevent
treatment
low
risk
toxic
find
led
sever
clinic
trial
ongo
studi
efficaci
chloroquin
hydroxychloroquin
patient
hydroxychloroquin
thu
use
itali
treatment
patient
despit
absenc
efficaci
data
clinic
set
light
data
recommend
rheumat
patient
chronic
take
antimalari
drug
discontinu
consid
antivir
efficaci
immunomodulatori
rather
immunosuppress
effect
pulmonari
complic
human
patient
due
exuber
local
inflammatori
respons
diffus
alveolar
damag
patient
die
sar
lung
consolid
edema
mucopurul
materi
bronchial
tree
microscop
examin
alter
diffus
alveolar
damag
hyalin
membran
fibrin
format
neutrophil
macrophag
infiltr
detect
interstitium
alveoli
similar
featur
note
human
autopsi
report
avail
mer
infect
cytokin
chemokin
play
key
role
immun
respons
viral
infect
alter
product
demonstr
sar
mer
coronaviru
infect
alter
level
shown
like
due
low
synthesi
antivir
cytokin
interferon
ifn
concert
increas
level
proinflammatori
cytokineschemokin
pathogen
consequ
among
interleukin
il
proinflammatori
cytokin
shown
significantli
elev
patient
sever
compar
uncompl
sar
mer
infect
recent
preliminari
data
china
report
high
plasma
level
cytokin
includ
relat
sever
prognosi
diseas
clear
implic
occurr
cytokin
storm
cr
tocilizumab
receptor
antibodi
use
clinic
treat
rheumatoid
arthriti
autoimmun
diseas
use
approv
treatment
varieti
clinic
condit
includ
cr
includ
clinic
condit
associ
chimer
antigen
receptor
tcell
cart
therapi
appear
induc
sever
lifethreaten
cytokin
releas
syndrom
singl
dose
tocilizumab
use
patient
china
suffer
sever
respiratori
syndrom
infect
dosag
mg
intraven
addit
routin
therapi
day
patient
recov
lung
opac
disappear
suggest
might
power
potenti
rescu
therapi
respiratori
distress
syndrom
potenti
role
biolog
could
hypothes
data
show
activ
inflammasom
sarscov
secret
studi
demonstr
inflammasom
activ
also
occur
infect
especi
within
lymphoid
cell
patient
increas
serum
anoth
potenti
treatment
evalu
relat
acut
respiratori
diseas
baricitinib
oral
drug
use
treat
rheumatoid
arthriti
patient
function
blocker
janu
kinas
jak
enzym
associ
intracellular
signal
includ
type
type
ii
ifn
signal
one
rational
use
base
fact
virus
util
protein
express
spike
bind
receptor
enter
cell
mechan
receptormedi
endocytosi
one
known
regul
receptor
mediat
endocytosi
kinas
term
protein
kinas
baricitinib
high
affin
inhibit
reason
inhibit
receptor
mediat
endocytosi
block
intracellular
entri
viru
may
also
function
intracellular
assembl
viru
particl
plasma
concentr
baricitinib
current
therapeut
dosag
mg
oral
daili
suffici
inhibit
thu
may
abl
reduc
viral
entri
inflamm
characterist
patient
anoth
import
aspect
patient
abl
initi
valid
rapid
type
ifn
respons
mechan
underli
defect
respons
complet
clear
sar
macrophag
dendrit
cell
abort
infect
natur
killer
cell
activ
viru
thu
suggest
defect
innat
immun
respons
alter
viru
clearanc
mous
model
use
relat
coronaviru
delay
typei
ifn
respons
ifn
level
peak
later
immun
respons
remain
elev
associ
mortal
sever
lung
diseas
due
recruit
highli
inflammatori
macrophag
lung
studi
human
sarscov
infect
also
strongli
suggest
dysregul
persist
elev
typei
ifn
respons
associ
sever
human
lung
diseas
mous
model
absenc
typei
ifn
signal
achiev
knockout
ifnreceptor
abolish
lung
mediat
lethal
data
also
suggest
second
possibl
explan
therapeut
effect
jak
inhibitor
baricitinib
sinc
block
downstream
signal
alpha
beta
ifn
receptor
situat
complic
find
earli
administr
mous
model
also
decreas
lung
diseas
suggest
time
durat
typei
ifn
respons
critic
whether
outcom
help
deleteri
impli
patient
jak
inhibit
therapi
may
decreas
ifn
respons
viru
would
caus
excess
viru
replic
also
might
less
risk
sever
lung
diseas
due
downregul
ifn
signal
pathway
illustr
difficult
balanc
adequ
immun
respons
prevent
viral
replic
overexuber
immun
respons
caus
sever
lung
patholog
role
type
ifn
role
block
ifni
pathway
therefor
requir
detail
studi
evas
immun
system
checkpoint
often
use
malign
cancer
cell
pathogen
escap
immun
surveil
one
interest
checkpoint
inhibitor
system
fig
checkpoint
neg
regul
immun
respons
aim
prevent
excess
inflammatori
respons
differ
trigger
thu
shown
downmodul
singl
strand
rna
viru
sensor
plasmacytoid
dendrit
cell
mous
model
coronaviru
infect
downmodul
macrophag
activ
interestingli
inhibit
posit
effect
coronaviru
infect
restor
ifn
product
increas
viru
clearanc
checkpoint
inhibitor
current
effect
use
therapeut
agent
varieti
cancer
minim
studi
human
infecti
diseas
although
function
clearli
defin
use
murin
model
lcmv
infect
fusion
protein
success
use
experiment
set
trial
inhibitori
antibodi
target
test
treatment
human
cancer
thu
suggest
intrigu
possibl
use
current
avail
checkpoint
inhibitor
treatment
trial
anoth
checkpoint
inhibitor
also
ongo
patient
scientif
research
possibl
therapi
base
knowledg
previou
coronavirus
data
recent
made
avail
chines
scientif
societi
likewis
social
health
polici
inform
contain
measur
base
learn
previou
epidem
order
optim
current
measur
epidemiolog
sarscov
china
learn
fundament
measur
earli
recognit
problem
strict
infect
control
identif
infect
patient
isol
measur
inclus
format
new
medic
sanitari
staff
health
system
design
new
hospit
ward
appropri
equip
inform
mass
social
media
part
measur
recent
italian
societi
rheumatolog
propos
set
practic
recommend
improv
manag
patient
decreas
risk
acquir
infect
particular
rheumat
patient
undergo
immunosuppress
therapi
tabl
gener
interrupt
therapi
use
rheumat
patient
advis
may
respons
onset
clinic
flare
rheumat
diseas
subsequ
use
immunosuppress
oral
glucocorticoid
may
equal
unsaf
patient
case
acquir
although
data
present
unavail
appear
import
maintain
chronic
therapi
strict
control
patient
order
evalu
specif
clinic
need
fact
infect
risk
rheumat
diseas
rheumatoid
arthriti
also
relat
diseas
activ
flare
due
therapi
discontinu
would
confer
higher
risk
infect
reason
rheumat
patient
long
term
oral
glucocorticoid
treatment
never
stop
abruptli
addit
kept
mind
end
therapi
may
also
lead
adren
crisi
prevent
measur
suggest
italian
tabl
recommend
propos
rheumat
diseas
pandem
ministri
health
must
appli
everyon
particular
rheumat
patient
undergo
immunosuppress
therapi
patient
therefor
strongli
encourag
avoid
social
contact
maintain
isol
chronic
therapi
guarante
rheumat
patient
also
week
outbreak
routin
outpati
clinic
close
nation
health
system
author
peopl
move
specif
reason
health
issu
need
biolog
therapi
avail
hospit
tocilizumab
baricitinib
may
start
use
treat
sever
pneumonia
case
avail
must
guarante
treatment
rheumat
patient
use
compound
rheumat
patient
develop
symptom
infect
import
follow
guidelin
suggest
rheumatolog
commun
immunosuppress
therapi
paus
durat
infect
one
except
hydroxychloroquin
may
therapeut
potenti
infect
therefor
stop
patient
take
rheumat
diseas
mention
possibl
blockad
use
jak
inhibitor
could
benefici
effect
sever
lung
diseas
nt
yet
know
enough
recommend
continu
agent
sinc
could
advers
affect
viral
clearanc
much
studi
kinet
lung
relat
immun
respons
onset
cr
therefor
need
clarifi
recommend
patient
agent
epidemiolog
scenario
rapidli
chang
daili
still
knowledg
infect
rate
cours
rheumatolog
condit
therefor
nation
intern
registri
strongli
encourag
understand
impact
infect
specif
rheumat
diseas
treatment
risk
factor
poor
outcom
italian
societi
rheumatolog
establish
registri
march
data
collect
although
observ
epidemiolog
ground
quit
surpris
limit
number
rheumat
patient
contact
us
infect
furthermor
intern
registri
support
america
colleg
rheumatolog
european
leagu
rheumat
rheumatolog
societi
worldwid
launch
meantim
import
patient
reassur
consult
made
avail
use
media
exclud
persontoperson
relationship
minim
risk
infect
